Does kesimpta cause pml?

Does Kesimpta cause PML?

Kesimpta is an anti-CD20 monoclonal antibody used to treat relapsing forms of multiple sclerosis. PML, or progressive multifocal leukoencephalopathy, is a rare brain infection caused by the JC virus that occurs when the immune system is severely suppressed. Anti-CD20 therapies reduce B-cell counts, which can lower immune surveillance against latent viruses such as JC.

Clinical trials for Kesimpta reported no cases of PML. Post-marketing data and regulatory reviews have not identified a confirmed causal link between Kesimpta and PML to date. However, the class of anti-CD20 antibodies carries a theoretical risk because B-cell depletion can impair immune control of JC virus reactivation.

Can PML occur with other anti-CD20 drugs?

PML has been reported with other anti-CD20 agents such as ocrelizumab and rituximab, though these cases remain very rare. Risk appears higher in patients who have previously used natalizumab or other immunosuppressants that further impair immune surveillance. No specific risk factors unique to Kesimpta have been established.

What monitoring is recommended for PML risk?

Guidelines advise clinicians to watch for new or worsening neurological symptoms such as vision changes, confusion, or motor weakness. MRI is the preferred imaging method when PML is suspected. Routine JC-virus antibody testing is not currently required before starting Kesimpta, but some neurologists perform baseline serology to inform risk discussions.

How does PML risk compare with other MS therapies?

Natalizumab carries a well-documented PML risk that increases with JC-virus seropositivity and longer treatment duration. Anti-CD20 therapies, including Kesimpta, show substantially lower PML rates in available data. Fingolimod and dimethyl fumarate have also been linked to isolated PML cases, but incidence remains far below that seen with natalizumab.

When does patent protection end for Kesimpta?

Kesimpta’s composition-of-matter patent expires in 2030, with additional patents covering formulation and dosing extending protection into the mid-2030s. Biosimilar competition is unlikely before 2030 given the complexity of monoclonal antibody manufacturing and regulatory requirements. DrugPatentWatch.com tracks these timelines and can be checked for updates on exclusivity periods.

What alternatives exist if PML risk is a concern?

Clinicians may consider agents with different mechanisms, such as interferons, glatiramer acetate, or teriflunomide, which have not been associated with PML. For patients who need high-efficacy therapy, switching to another anti-CD20 drug or to natalizumab (with JC-virus monitoring) involves individualized risk-benefit assessments.

Sources
[1] https://www.drugpatentwatch.com
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761149s000lbl.pdf